Abstracts Archive - Page 338 of 2425 - ACR Meeting Abstracts

Abstract Number: 2020 • ACR Convergence 2023
Exploring Experiences and Perspectives of Canadian Patients with Lupus Nephritis Through Photovoice
Francesca Cardwell¹, Susan Elliott¹, Megan R.W. Barber², Kim Cheema², Sydney George³, Adrian Boucher³ and Ann Clarke⁴, ¹University of Waterloo, Waterloo, ON, Canada, ²University of Calgary, Calgary, AB, Canada, ³GlaxoSmithKline, Mississauga, ON, Canada, ⁴University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada
Background/Purpose: LN is a major cause of morbidity and mortality and develops in up to 60% of adult SLE patients. The experiences of patients with…
Abstract Number: 1931 • ACR Convergence 2023
Anti-Ku Antibodies: A Case Series
Raquel Ugena García¹, Cristina Calomarde Gomez¹, Joan Climent² and Lourdes Mateo Soria², ¹Rheumatology department. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Anti-Ku antibodies (Abs) were initially described in patients with polymyositis and scleroderma. Subsequently, an association has been demonstrated with other systemic autoimmune diseases (SADs),…
Abstract Number: 1964 • ACR Convergence 2023
Penn State Registry of Inflammatory Myopathies (PRIMO) Provides Insights into Disease Features and Co-Morbidity Screening Utilization
Jacob Colello¹, Kirsten Riggle¹, Galen Foulke², Peri Newman¹, Jamie Carter¹ and Nancy Olsen¹, ¹TE-Penn State MS Hershey Medical Center, Hershey, PA, ²Penn State MS Hershey Medical Center, Hershey, PA
Background/Purpose: Dermatomyositis (DM) is a relatively rare condition with significant morbidity and mortality across the lifespan.Recent advances in diagnostics and therapeutics have significant potential to…
Abstract Number: 1950 • ACR Convergence 2023
Thromboembolic Risk Associated with Intravenous Immune Globulin Use in Patients with Idiopathic Inflammatory Myopathy: A Large Database Study
Rohan Mehta¹, Mike Putman² and Didem Saygin³, ¹Medical College of Wisconsin, Milwaukee, WI, ²Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Intravenous immune globulin (IVIG) recently received regulatory approval for the treatment of dermatomyositis, one of the idiopathic inflammatory myopathies (IIM). The pivotal randomized trial…
Abstract Number: 1944 • ACR Convergence 2023
Characterization of Interstitial Pneumonia with Autoimmune Features (IPAF) in a National Referral Centre
Arturo Llobell¹, Belén Atienza-Mateo², David Iturbe-Fernández³, Victor Mora-Cuesta³, Marcos Lopez-Hoyos⁴, Jose Cifrian⁵ and Ricardo Blanco⁶, ¹Parc Tauli University Hospital, Barcelona, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital, Santander, Spain, ⁴Marques de Valdecilla University Hospital-IDIVAL, Santander, Spain, ⁵Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) comprises a wide range of disorders categorized by clinical, radiographic and pathologic findings that is closely associated with autoimmune connective…
Abstract Number: 2049 • ACR Convergence 2023
Vaccination Coverage and Caregiver Perspectives for Children with Rheumatic Diseases Compared to Healthy Controls
Shine Vazhappilly¹, Racheal Githumbi², Nicole Johnson², Otto G Vanderkooi² and Heinrike Schmeling², ¹Saba University, Blue Ash, OH, ²University of Calgary, Calgary, AB, Canada
Background/Purpose: Children with rheumatic diseases (RD) have an increased incidence of infections and their complications, both from underlying disease activity and immunosuppressive treatments. Vaccines have…
Abstract Number: 2043 • ACR Convergence 2023
Phenotype of Musculoskeletal Manifestations in a Canadian Inception Cohort of Pediatric Patients with Inflammatory Bowel Disease
Emily Dzongowski¹, Michael Miller¹, Melanie Schmidt¹, Nidhi Rashmikant Suthar¹, Thomas D Walters², Anne Griffiths², Wael El-Matary³, Eric Benchimol², Jennifer deBruyn⁴, Roberta A Berard¹ and Eileen Crowley¹, ¹Children's Hospital - London Health Sciences Centre, London, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³University of Manitoba, Winnipeg, MB, Canada, ⁴Alberta Children's Hospital, Calgary, AB, Canada
Background/Purpose: Musculoskeletal (MSK) manifestations, including arthritis and arthralgia, are among the most common extraintestinal manifestations (EIMs) of inflammatory bowel disease (IBD), reported in 20-30% of…
Abstract Number: 1824 • ACR Convergence 2023
Breakthrough COVID-19 and Severity After Vaccination Among Pregnant Persons with Rheumatic Diseases
Anna Sutton¹, Carolyn Hilliard², Qiuyuan Qin³, Alfred Jared Anzalone⁴, Mary Toth⁵, Rena Patel⁶ and Namrata Singh⁷, ¹Department of Epidemiology, University of Washington School of Public Health, Woodinville, WA, ²Department of Internal Medicine SSM Saint Louis University, St. Louis, MO, ³Department of Public Health, University of Rochester, Rochester, NY, ⁴Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, ⁵Nemours Foundation, Orlando, FL, ⁶Departments of Medicine and Global Health, University of Washington, Seattle, WA, ⁷University of Washington, Bellevue, WA
Background/Purpose: Acknowledgment: Contributed on behalf of the National COVID Cohort Collaborative (N3C) ConsortiumIndividuals with rheumatologic diseases (RD) are at higher risk for severe COVID-19 compared…
Abstract Number: 2033 • ACR Convergence 2023
Sex Differences in Patient-Reported Outcomes in Patients with Rheumatoid Arthritis After Starting a New Disease-Modifying Antirheumatic Medication
John Davis¹, Sara Achenbach², Courtney Arment¹, Delamo Bekele¹, Vanessa Kronzer¹, Thomas Mason¹, Elena Myasoedova¹, Lynne Peterson¹, Kerry Wright¹ and Cynthia Crowson¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: Patient-Reported Outcome Measurement Information System (PROMIS®) measures are valued in the assessment of health outcomes for patients with rheumatoid arthritis (RA). However, little is…
Abstract Number: 1790 • ACR Convergence 2023
Expansion of CD8+ TCRVβ9+ T Cells in the Peripheral Blood of HLA-B27+ Patients with Axial Spondyloarthritis
Caroline Bauchiero¹, Micah Lefton¹, Stephanie Sinnappan², Jeffrey Sparks³ and Joerg Ermann⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Studies in human HLA-B27 transgenic rats largely discredited the idea that CD8+ T cells are key drivers of disease in axial spondyloarthritis (axSpA). However,…
Abstract Number: 1960 • ACR Convergence 2023
From Clinical Amyopathy to Severe Oropharyngeal Dysphagia in Pure Dermatomyositis: A Greater Extent of Muscle Weakness Is Associated with a Higher Cancer Prevalence
Hao Cheng Shen¹, Victoria Ivensky², Yves Troyanov³, Josiane Bourre-Tessier¹, Farah Zarka², Sabrina Hoa⁴, Jessica Nehme², Jean-Paul Makhzoum⁵, Anne-Marie Mansour², Rosalie-Selene Meunier², Alexandra Mereniuk², Darosa Lim⁶, Jean-Pierre Raynauld¹, Eric Rich¹, Jean-Richard Goulet¹, Marianne Landry⁷, Maude Bouchard-Marmen⁸, Valerie Leclair⁹, Hugues Allard-Chamard¹⁰, Marie Hudson¹¹, Erin O'Ferrall¹², Rami Massie¹², Jason Karamchandani¹³, Benjamin Ellezam¹⁴, Ira N. Targoff¹⁵, Minoru Satoh¹⁶, Marvin Fritzler¹⁷, Jean-Luc Senecal¹, Alain Meyer¹⁸ and Oceane Landon-Cardinal¹, ¹Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, ²Hôpital du Sacré-Coeur de Montréal, Université de Montréal, Montreal, QC, Canada, ³Hôpital du Sacré-Coeur de Montréal, Centre hospitalier de l'Université de Montreal (CHUM), Université de Montréal, Montreal, QC, Canada, ⁴University of Montreal, Brossard, QC, Canada, ⁵Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Hôpital de LaSalle, Montreal, QC, Canada, ⁸CHU de Québec, Université Laval, Quebec City, QC, Canada, ⁹Jewish General Hospital, McGill University, Montreal, QC, Canada, ¹⁰Université de Sherbrooke, Sherbrooke, QC, Canada, ¹¹McGill University, Montréal, QC, Canada, ¹²Montreal Neurological Institute, McGill University, Montreal, QC, Canada, ¹³McGill University Health Center (MUHC), McGill University, Montreal, QC, Canada, ¹⁴CHU Sainte-Justine, Université de Montréal, Montreal, QC, Canada, ¹⁵Veteran's Affairs Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁷University of Calgary, Calgary, AB, Canada, ¹⁸Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Background/Purpose: The risk of cancer is increased in patients with pure dermatomyositis (DM), i.e. patients with a DM rash and without an anti-MDA-5 syndrome, a…
Abstract Number: 2040 • ACR Convergence 2023
Distinguishing Multisystem Inflammatory Syndrome in Children from Typhus Using Artificial Intelligence: MISC vs. Endemic Typhus (AI-MET)
Angela Chun¹, Abraham Bautista-Castillo², Isabella Osuna¹, Kristiana Nasto¹, Flor Munoz³, Gordon Schutze¹, Sridevi Devaraj¹, Eyal Muscal⁴, Marietta De Guzman⁵, Kristen Sexson Tejtel¹, Ioannis Kakadiaris² and Tiphanie Vogel¹, ¹Baylor College of Medicine / Texas Children's Hospital, Houston, TX, ²Computational Biomedicine Lab University of Houston, Houston, TX, ³Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, ⁵Baylor College of Medicine, Houston, TX
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) following SARS-CoV2infection is a recognized mimic of other inflammatory disorders, including Kawasaki Disease and macrophage activation syndrome. However,…
Abstract Number: 1974 • ACR Convergence 2023
Comparison of Gait Spatiotemporal Measures Between Patients with Insertional Achilles Tendinopathy or Midportion Achilles Tendinopathy
Hayley Smitheman¹, Kayla Seymore¹, Andy Smith¹, Morgan Potter¹, Nabeel Alghamdi¹ and Karin Silbernagel², ¹University of Delaware, Newark, DE, ²University of Delaware, Avondale, PA
Background/Purpose: Insertional and midportion Achilles tendinopathy (AT) are painful injuries affecting both active and sedentary populations. Patients with AT present with pain with loading, often…
Abstract Number: 1454 • ACR Convergence 2023
Neuropsychiatric Systemic Lupus Erythematosus in Children: A Scoping Review
Alexandra Theisen¹, Ekemini Ogbu², Emily Beil³, Onengiya Harry⁴, Simone Appenzeller⁵, Ryan Kammeyer⁶, Hanne Van der Heijen⁷, Andrea Knight⁸, Hannah Craven⁹ and Martha Rodriguez¹⁰, ¹Saint Louis University School of Medicine, SSM Health Cardinal Glennon Children's Hospital, St. Louis, MO, ²Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Johns Hopkins University, Cincinnati, OH, ³Baylor College of Medicine / Texas Children's Hospital, Houston, TX, ⁴Brenner Children's Hospital - Wake Forest Baptist Health, Winston-Salem, NC, ⁵UNICAMP, Campinas, Brazil, ⁶University of Colorado School of Medicine, Children's Hospital Colorado, Denver, CO, ⁷Boston Children's Hospital, Harvard Medical School, Boston, MA, ⁸The Hospital for Sick Children, Toronto, ON, Canada, ⁹Ruth Lilly Medical Library, Indiana University School of Medicine, Indianapolis, IN, ¹⁰Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) remains a challenging entity to diagnose and treat. The clinical heterogeneity of NPSLE coupled with the difficulty with attribution…
Abstract Number: 2035 • ACR Convergence 2023
Intimate Partner Violence Is Associated with a Poorer Health-Related Quality of Life (HR-QoL) in Women with Systemic Lupus Erythematous
Emmanuel Campos-Tinajero¹, Griselda Serna-Peña², Jorge A. Esquivel-Valerio¹, Rodrigo J. Castillo-de la Garza³, Gisela García Arellano⁴, Pablo Gamez-Siller¹, Estefania Aguilar-Rivera⁵, Patricia L. Gonzalez-Garcia¹ and Dionicio A. Galarza-Delgado⁶, ¹Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ²Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ³Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁵Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁶Hospital Universitario UANL, Monterrey, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is an inflammatory, multisystemic, chronic disease more prevalent in women and can significantly impact health-related quality of life (HRQoL).1 Sociodemographic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].